Oryzon Genomics SA ORY

PMS is a severely disabling genetic disorder related to autismU.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important Project of Common European Interest (IPCEI) on HealthThe study is being advanced in collaboration with the Spanish Phelan–McDermid Syndrome Association MADRID and CAMBRIDGE, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage

MADRID and CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: HC Wainwright 28th Annual Global Investment Conference 2026, September 14-16Location: Lotte New York Palace Hotel, New York, United StatesPresentation date and time: September 15, 10:30 am ET European Main MidCap Event

Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data presented at EHA-2026 showed a high composite complete remission (CRc) rate of 67% in heavily pretreated FLT3-mutated R/R AML patients, together with a favorable safety profile MADRID and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS mutations; the triplet continued to demonstrate a favorable safety profileIn FLT3-mutated refractory-relapsed patients, iadademstat with gilteritinib continued to show a favorable safety profile and a high CRc rate of 67%Enrollment initiated in Phase II trial of iadademstat in essent

Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also received in a corresponding Canadian patent application MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trade

Issued 4,444,445 new ordinary shares Priced at €2.70 per share, representing a 14.15% discount on the five-day VWAP and a 12.68% discount to the June 30 closing priceThe transaction has been structured as a capital increase without the issuance of warrants Proceeds will be used to advance the Company's clinical development programs and support other corporate initiatives The Social Impact Fund, managed by COFIDES, has committed to invest €25 million in future capital increases to support Oryzon'

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demonstrate a favorable safety profileAll patients with TP53 or RAS pathway mutations achieved a complete response, showcasing the activity of the iadademstat combination across genomically defined adverse-risk subgroups and its potential in these populationsIn FLT3-mutated refractory-relapsed patients

As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical developments, investors are increasingly focusing on companies with strong growth potential and high insider ownership. In such an environment, stocks that combine robust growth prospects with significant insider stakes can offer a compelling proposition, as they may align management interests with those of shareholders while potentially capitalizing on market opportunities.

MADRID and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadademstat in patients with essential thrombocythemia (ET). IDEAL (IaDademstat treatment for EssentiAL thrombocythemia) is a multicenter, single-arm Phase II study being conducted in Spain in adult

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-month OS of 74% In FLT3‑mutated refractory-relapsed setting, iadademstat with gilteritinib has shown favorable safety profile and a high CRc rate (67%) MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical

European markets have recently experienced modest gains, with the pan-European STOXX Europe 600 Index benefiting from easing geopolitical tensions and strong corporate earnings. For investors interested in exploring beyond the well-known companies, penny stocks—often smaller or newer firms—can still hold significant potential despite their somewhat outdated name. In this article, we explore several European penny stocks that stand out for their financial resilience and growth potential.

In recent weeks, the pan-European STOXX Europe 600 Index has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, despite pressures from potential U.S. tariff increases on EU goods. As investors navigate this landscape, growth companies with high insider ownership can be appealing due to their potential for alignment of interests between management and shareholders, offering a unique edge in today's market environment.

Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June MADRID and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that it will participate at the following upcoming events: Bio-Equity Europe 2026, May 4-6Location: Congress Centre, Prague, Czech RepublicPresentation date and time: May 5, 9:45h

Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline perso